Identification of an argpyrimidine-modified protein in human red blood cells from schizophrenic patients: A possible biomarker for diseases involving carbonyl stress
Y.I. Ishida(Meiji Pharmaceutical University), Yuki Ogasawara(Meiji Pharmaceutical University), Mitsuhiro Miyashita(Tokyo Metropolitan Institute of Medical Science), Shoichi Nishimoto(Meiji Pharmaceutical University), Makoto Arai(Tokyo Metropolitan Institute of Medical Science), Yosuke Kibune(Meiji Pharmaceutical University), Tasuku Kayama(Tohoku University), Yasue Horiuchi(National Taiwan University), Toshihiro Suzuki(Meiji Pharmaceutical University), Satoshi Koike(Tokyo Metropolitan Institute of Medical Science), Masanari Itokawa(Fujita Health University)
Cited by 19
Related Papers
Improving polygenic prediction in ancestrally diverse populations
|Nature Genetics|2022|714
Structure of pathological TDP-43 filaments from ALS with FTLD
|Nature|2021|326
Comparative Analyses of Copy-Number Variation in Autism Spectrum Disorder and Schizophrenia Reveal Etiological Overlap and Biological Insights
|Cell Reports|2018|264
Brain Cannabinoid CB2 Receptor in Schizophrenia
|Biological Psychiatry|2009|184
Enhanced Carbonyl Stress in a Subpopulation of Schizophrenia
|Archives of General Psychiatry|2010|166